Pidotimod + Placebo
ApprovedCompleted 0 watching 0 views this week🔥 Hot
80
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Recurrent Respiratory Tract Infections
Conditions
Recurrent Respiratory Tract Infections
Trial Timeline
Aug 4, 2021 → Nov 4, 2021
NCT ID
NCT04322669About Pidotimod + Placebo
Pidotimod + Placebo is a approved stage product being developed by Almirall for Recurrent Respiratory Tract Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT04322669. Target conditions include Recurrent Respiratory Tract Infections.
Hype Score Breakdown
Clinical
30
Activity
20
Company
5
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04322669 | Approved | Completed |
Competing Products
20 competing products in Recurrent Respiratory Tract Infections